http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 07:03:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/XORTX+appoints+Mika+Grasso+as+co-CEO%2C+advances+gout+drug+program/26644118.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) appointed Mika Grasso as co-CEO responsible for finance and public markets, the company announced June 15. The pharmaceutical company also provided updates on its drug development programs, particularly its lead gout treatment XRx-026.</p><p>Grasso, 28, has served as a director of the company since March 24, 2026. He previously worked as an investment manager at a family office and held positions at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and BS in Business Administration from the University of Colorado Boulder.</p><p>The company said it received feedback http://www.streetinsider.com/Corporate+News/XORTX+appoints+Mika+Grasso+as+co-CEO%2C+advances+gout+drug+program/26644118.html Mon, 15 Jun 2026 07:03:40 -0400 XRTX http://www.streetinsider.com/Management+Changes/XORTX+appoints+Mika+Grasso+as+co-CEO%2C+advances+gout+drug+program/26644118.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) appointed Mika Grasso as co-CEO responsible for finance and public markets, the company announced June 15. The pharmaceutical company also provided updates on its drug development programs, particularly its lead gout treatment XRx-026.</p><p>Grasso, 28, has served as a director of the company since March 24, 2026. He previously worked as an investment manager at a family office and held positions at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and BS in Business Administration from the University of Colorado Boulder.</p><p>The company said it received feedback http://www.streetinsider.com/Management+Changes/XORTX+appoints+Mika+Grasso+as+co-CEO%2C+advances+gout+drug+program/26644118.html Mon, 15 Jun 2026 07:03:40 -0400 XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+Jun+15/26644059.html si-local-file:///var/storage/secattach/20260615/26644059.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+Jun+15/26644059.html Mon, 15 Jun 2026 07:00:00 -0400 O.28734418 XRTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+Jun+15/26644059.html si-local-file:///var/storage/secattach/20260615/26644059.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+Jun+15/26644059.html Mon, 15 Jun 2026 07:00:00 -0400 O.28734418 XRTX http://www.streetinsider.com/Corporate+News/XORTX+to+voluntarily+delist+from+TSX+Venture+Exchange/26641872.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) announced it will voluntarily delist its common shares from the TSX Venture Exchange following a board of directors' approval. The pharmaceutical company will continue trading on Nasdaq and maintain reporting requirements in Alberta, British Columbia and Ontario.</p><p>The Calgary-based company cited cost reduction and regulatory simplification as primary reasons for the decision. XORTX stated the dual listing no longer justified associated exchange fees and administrative requirements across different regulatory environments.</p><p>The delisting aims to eliminate duplicate exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing the XRx-026 program for gout treatment. The http://www.streetinsider.com/Corporate+News/XORTX+to+voluntarily+delist+from+TSX+Venture+Exchange/26641872.html Fri, 12 Jun 2026 17:01:24 -0400 XRTX